However, since p53 acts as a tetramer, expressed TP53 mutant variants can also exert a dominant negative (DN) effect over their wild-type counterpart, and additionally they can arm cancer cells with novel oncogenic gain-of-function (GOF) activities (4–6). The gene discussed is TP53; the disease is cancer.